Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity. 2017

Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Solna, Sweden. Johanna.holm@ki.se.

Subtype heterogeneity for breast cancer risk factors has been suspected, potentially reflecting etiologic differences and implicating risk prediction. However, reports are conflicting regarding the presence of heterogeneity for many exposures. To examine subtype heterogeneity across known breast cancer risk factors, we conducted a case-control analysis of 2,632 breast cancers and 15,945 controls in Sweden. Molecular subtype was predicted from pathology record-derived IHC markers by a classifier trained on PAM50 subtyping. Multinomial logistic regression estimated separate ORs for each subtype by the exposures parity, age at first birth, breastfeeding, menarche, hormone replacement therapy use, somatotype at age 18, benign breast disease, mammographic density, polygenic risk score, family history of breast cancer, and BRCA mutations. We found clear subtype heterogeneity for genetic factors and breastfeeding. Polygenic risk score was associated with all subtypes except for the basal-like (Pheterogeneity < 0.0001). "Never breastfeeding" was associated with increased risk of basal-like subtype [OR 4.17; 95% confidence interval (CI) 1.89-9.21] compared with both nulliparity (reference) and breastfeeding. Breastfeeding was not associated with risk of HER2-overexpressing type, but protective for all other subtypes. The observed heterogeneity in risk of distinct breast cancer subtypes for germline variants supports heterogeneity in etiology and has implications for their use in risk prediction. The association between basal-like subtype and breastfeeding merits more research into potential causal mechanisms and confounders. Cancer Res; 77(13); 3708-17. ©2017 AACR.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
October 2018, Cancer research,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
April 2021, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
December 2022, Breast (Edinburgh, Scotland),
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
October 2020, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
January 2023, Neurosurgery,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
July 2021, Oncogene,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
July 2022, Cell reports. Medicine,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
March 2020, British journal of cancer,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
September 2018, JAMA oncology,
Johanna Holm, and Louise Eriksson, and Alexander Ploner, and Mikael Eriksson, and Mattias Rantalainen, and Jingmei Li, and Per Hall, and Kamila Czene
January 2011, Revista medica del Instituto Mexicano del Seguro Social,
Copied contents to your clipboard!